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Smooth musc le cells from spon taneous ly h y p e r t e n -
sive ra ts (SHR) prol i fera te in cu l tu re faster t h a n 
those isolated from sex- a n d age-matched Wis tar -
Kyoto (WKY) an ima l s . T h e r e w a s n o difference in 
t he k ine t ics of S6 k inase act ivat ion in t h e two cul-
tures , b u t later metabol ic even ts associated w i t h 
pro l i fe ra t ion w e r e s t imula ted ear l ier i n SHR cells 
t h a n in WKY, eg, act ivat ion of o r n i t h i n e decarbox-
ylase . Both cell types e labora ted a n extens ive extra-
cel lular mat r ix in cu l ture composed of a different 
b l e n d of connect ive t i ssue macromolecu les . Mat r ix 
ma te r i a l from SHR cells w a s m o r e s t imula to ry to 
g r o w t h of WKY cul tures t h a n the i r o w n matr ices . 
Ang io t ens in s t imula ted t h e g r o w t h a n d syn thes i s 
of extra-cel lular ma t r ix ma te r i a l i n SHR m o r e t h a n 
in WKY der ived vascular smoo th musc le cell cul-
tu res . A m J H y p e r t e n s 1991;4:183-188 
KEY W O R D S : Ang io tens in , vascu la r smoo th musc le 
g r o w t h me tabo l i sm. 
The well established concepts embodied in the "response to injury theory," as proposed by Ross and Glomset, 1 has provided a model for the study of the many factors and their interac-
tion responsible for the pathogenesis of vascular disease 
under situations where frank denudat ion of the endo-
thelium has taken p l a c e . 2 - 4 There is n o w evidence to 
suggest that both hyper t rophy and hyperplasia can 
occur in the absence of any apparent damage to the 
endothelial l a y e r . 5 - 7 For these processes to take place we 
need to invoke the influences of compounds that are 
normally present in the intact blood vessel wall. 
Candidates for the processes ment ioned abo r"* in-
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elude compounds that have been characterized as 
growth factors, as well as a number of molecules nor-
mally associated with the structural components of the 
vessel wall (see Figure 1). Among these extracellular 
matrix compounds , thrombospondin (TS) has certain 
attributes which strongly suggest that it could play an 
important role in a variety of processes that eventually 
lead to the development of vascular d i s e a s e . 8 - 1 0 The 
vasoactive peptide hormones are another group of mole-
cules that have received attention wi th regard to their 
pathogenic potential. In this respect angiotensin II (Ang 
II) has been suggested to induce irreversible vascular 
c h a n g e s . 1 1 1 2 Clearly, the latter is a candidate eminently 
suited to playing a role in the chronic progressive induc-
tion of the vascular structural changes that are part and 
parcel of essential hypertension (EHT), since more than 
two thirds of patients with EHT exhibit elevated plasma 
r e n i n / A n g II levels relative to the height of their blood 
p r e s s u r e . 1 3 1 4 Recent reports have shown that indeed 
Ang II is capable of stimulating a number of metabolic 
events that may lead to smooth muscle proliferative 
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FIGURE 1. Schematic representation of vessel wall and some 
components thereof which may contribute to the pathogenesis of 
vascular disease. Matrix molecules: fibronectin (FN); laminin 
(LN); thrombospondin (TS); tenascin (TN); collagen (COL); heparan 
sulfate/heparin and elastin (HS). Growth Factors/Stimulators: 
epidermal growth factor (EGF); basic fibroblast growth factor 
(FGFb); platelet derived growth factor (PDGF); transforming 
growth factor β (TGFß); angiotensin (All) and low density lipopro­
tein (LDL). Furthermore, within the matrix compounds such as 
LDL and basic fibroblast growth factor can be bound. In the course 
of the normal turnover of matrix molecules which accompanies the 
dynamic process of tissue remodelling, peptide fragments having 
EGF domains can be generated and some of the stimulatory proper­
ties of this growth factor may become manifest. The compounds 
known to possess such EGF domains include LN, TS, and TN, a 
recently discovered matrix glycoprotein also found in vascular 
tissue.39 Both endothelial and smooth muscle cells are capable of 
secreting a number of growth factors without or with agonist 
stimulation, eg, Ang II. These events may lead to either hyper­
trophy or hyperplasia as well as the promotion of migration into 
the intimai space (see Discussion). 
behavior . 1 1 - 1 2 - 1 5 The induction of c-fos, c-myc, and PDGF 
A chain gene expression in cultures of rat smooth mus ­
cle cells by Ang I I , 1 1 ' 1 2 as well as its ability to stimulate 
protein syn thes i s , 1 5 ' 1 6 strongly suggest that chronic expo­
sure of vascular smooth muscle to this vasoactive pep­
tide may have pathologic consequences. 
We report here on our investigations with Ang II 
using cultured smooth muscle cells from spontaneously 
hypertensive rats (SHR) and their normotensive Wistar-
Kyoto (WKY) litter mates. We also report here on the use 
of plasma-derived serum (PDS) in conjunction with 
Ang II for the prolonged propagation of cultured rat 
smooth muscle cells. Our rationale for the use of PDS 
is that under normal physiologic conditions medial 
smooth muscle cells would not come into contact with 
serum from whole blood, but are rather "ba thed by a 
filtrate of p l a s m a , " 1 7 essentially similar to the non-
mitogenic preparat ions we have used in some of these 
studies. 
MATERIALS A N D M E T H O D S 
All materials and media for tissue culture were obtained 
from sources already described. 1 8 The radioisotopes 
used in the studies described herein were purchased 
from Amersham Radiochemical, Amersham, Bucking­
hamshire , England. Immunologic reagents were ob­
tained from Dakopatts, Glostrup, Denmark. SHR and 
WKY rats were supplied by Madörin/BRL, Frenken-
dorf, Switzerland. 
All cell culture techniques and details of procedures 
employed for the isolation of vascular smooth muscle 
cells (VSMC) from rats (SHR and WKY) have been re­
ported before. Cell numbers (growth kinetics) were de­
termined on cell suspensions following enzymatic dis­
aggregation of cell layers and counting in a Coulter 
(Hialeah, FL) counter . 1 8 
Plasma-derived serum (PDS) was prepared by the 
method of Ross and Kariya 2 2 and each batch was as­
sessed after sterilization by filtration for its mitogenic 
potential. Samples (10% final concentration) that st imu­
lated the incorporation of [ 3 H]-thymidine into D N A to 
levels greater than 5% of that obtained using 10% whole 
blood serum were rejected; PDS was used in experi­
ments at a final concentration of 1%. 
Preparation of extracellular matrix (ECM)-coated 
plastic culture vessels and dishes, as well as all proce­
dures for S6 kinase activation of quiescent cultures, 
were described. 1 8 
The incorporation of [ 3 H]-thymidine into D N A was 
measured as described before 2 3 and the kinetics of [ 3 H]-
glycine incorporation into ECM protein was performed 
as described by ourselves and o the r s . 1 6 ' 1 9 Assays for the 
activation of ornithine decarboxylase (ODC) were 
carried out as reported by Ho vis et a l . 2 4 
RESULTS 
When quiescent VSMC cultures (SHR and WKY) were 
exposed to 10% fetal calf serum (FCS) there was a dif­
ferential t ime-dependent activation of a number of im­
portant growth associated metabolic events which in­
cluded S6 kinase, ornithine decarboxylase, D N A 
synthesis, and [ 3 H]-thymidine incorporation (Figure 2). 
The temporal relationship be tween these events has 
been well documen ted 2 5 and the time intervals 
observed between the induction of, for example S6 ki­
nase and ODC reflect the proliferation rates of the stimu­
lated cultures. SHR-derived cells exhibited shorter time 
intervals between the induction of S6 kinase and O D C 
than cells from WKY sources (Figure 2). Al though we 
have shown previously that Ang II differentially stimu­
lated S6 kinase activation in quiescent cultures of VSMC 
from SHR and WKY sources , 2 6 we did not observe any 
induction of ODC activity or stimulation of [ 3 H]-thymi-
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FIGURE 2. Kinetics of activation of important metabolic events 
leading to cell proliferation in VSMC from SHR and WKY rats. 
Quiescent cells were exposed to fetal-calf serum (10%) and the 
activity of S6 kinase, ODC, and the incorporation levels of [3H]-
thymidine into DNA determined (see Methods). The data repre­
sents the mean values from two experiments performed on a pair of 
SHR and WKY isolates at same passage number and at similar cell 
densities. Closed symbols represent data from SHR and open sym­
bols, WKY cultures. 
dine incorporation by this agonist w h e n added to 
serum-free medium. 
The VSMC from SHR and WKY sources elaborated 
extracellular matrices during long-term culture in pres­
ence of Na ascorbate, which consisted of a complex 
blend of connective macro-molecules . 2 7 Proliferation 
rates of WKY cells were differentially stimulated w h e n 
they were cultured upon matrices elaborated either by 
themselves or SHR cells in previous passage (Figure 3). 
Growth rates of SHR cells were not significantly differ­
ent w h e n they were plated upon matrices elaborated by 
cells of either type (Figure 3). 
When quiescent cultures of VSMC from SHR were 
exposed to Ang II there was a t ime-dependent stimula­
tion of incorporation of [ 1 4C]-glycine and [ 3H]-glucosa-
mine into extracellular matrix material above levels ob­
served for serum-free medium controls (Figure 4). 
Similar findings were obtained with cells from normo­
tensive animals (data not shown). The data also sug­
gested a differential stimulation of glycoconjugate syn­
thesis by Ang II since the ratios for the incorporation of 
the two isotopic matrix precursors were significantly 
(P < .05) different, ( [ 3 H]/ [ 1 4 C]; 1.17 ± 0.2 for Ang II ν 
0.77 ± 0 . 2 for controls). 
Although under serum-free conditions Ang II was 
incapable of stimulating mitogenic behavior in VSMC, 
in the presence of 1% PDS cells from SHR exhibited an 
enhanced responsiveness to the agonist leading to a sig-
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FIGURE 3. Growth stimulation by extracellular matrix sub­
strata. VSMC were plated onto either gelatin-washed or matrix-
coated substrata18 and grown for 3 days with normal medium. 
Following the growth period wells were trypsinized and cell num­
bers determined (see Methods). The data is expressed as the per­
centage of stimulation in growth (cell number) on the different 
matrix preparations (from SHR or WKY) relative to growth on 
gelatinized plastic (100°/o) and represents the means ± SD of re­
peated (n = 4) experiments. The hatched blocks represent data for 
SHR and * indicates the significance of difference (P > .001) in cell 
numbers for WKY when plated upon either SHR-derived ECM or 
their own. 
nificant (P < .001) sustained increase in cell number 
(Figure 5). We also observed a minimal increase in prolif­
eration rates by cells from WKY rats exposed to Ang II 
and 1% PDS, which only reached significance (P < .01) 
after 9 days in culture. 
DISCUSSION 
VSMC from SHR sources exhibit elevated growth rates 
and enhanced responsiveness to growth stimulants 
(growth factors, hormones , and FCS) as compared to 
cells from WKY s o u r c e s . 1 8 ' 2 3 2 8 - 3 0 We have also reported 
on the differential stimulation of S6 kinase in the two 
cell types as a consequence of their exposure to Ang I I . 2 6 
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FIGURE 4. Kinetics of incorpora­
tion of radioactive matrix precursors 
into ECM macromolecules by VSMC 
from SHR. Quiescent cultures of 
SHR smooth muscle cells were ex­
posed to either [14C]-glycine or 
[3H]-glucosamine in the presence or 
absence of 100 nmol/L Ang II for the 
number of times shown. The determi­
nation of the levels of incorporation 
was performed as described under 
Methods and the data (mean 
values ± SD) is typical of that seen 
in a number of experiments (n = 4). 
Closed symbols represent cells 
maintained in the presence of Ang II 
and open, in its absence. 
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However, this agonist was unable to stimulate the acti­
vation of ODC or subsequent events leading to mitosis 
under serum-free conditions. We have also shown that 
other potential growth enhancers like low density lipo­
proteins (LDL) and thrombospondin (TS) behave in a 
similar m a n n e r . 2 0 ' 2 1 FCS, which contains a number of 
mitogens for VSMC (ie, platelet derived growth factor 
(PDGF), basic fibroblast growth factor (FGF b ) , and epi­
dermal growth factor (EGF)) stimulated the induction of 
all three growth related metabolic events depicted in 
Figure 2. Cells from SHR responded faster to FCS in 
terms of ODC activation and [ 3 H]-thymidine incorpora­
tion than did their normotensive (WKY) counterparts; 
this is a reflection of their faster growth rates in culture. 
Ang II stimulation of matrix glycoconjugate synthesis 
(Figure 4) may contribute to the structural changes that 
are part and parcel of vascular disease. The extracellular 
matrix plays an important role in the maintenance of 
p h e n o t y p e , 1 0 ' 3 1 ' 3 2 and our observations that matrix mate­
rial from SHR stimulated the growth of WKY cells to a 
greater extent than that elaborated by themselves serves 
to emphasize the importance of this component of the 
vessel wall. We have summarized some of the current 
knowledge and some of our own findings in regard to 
the interactions of normal vessel wall components (Fig­
ure 1). Central to these observations is the evidence that 
Ang II is capable of stimulating the expression of a n u m ­
ber of important compounds which include PDGF A 
chain, TS, and TGF^. 3 3 The induction of PDGF A chain 
expression in VSMC exposed to Ang II has already been 
repor ted 1 1 and it may account for our observation of 
growth stimulation by Ang II of cells from SHR in pres­
ence of 1% PDS (Figure 5). We have found that cell 
isolates from SHR express and have receptors for 
P D G F ^ homodimer, whereas WKY-derived cells only 
express the growth factor but do not respond to it, since 
they lack A-type cell surface receptors . 3 4 The increase in 
cell number observed in cultures from hypertensive an­
imals maintained in 1 % PDS medium alone may also be 
accounted for by their responsiveness to PDGF A-chain 
homod imer . 3 4 The synthesis and secretion of the AA 
homodimeric form of PDGF by arterial smooth muscle 
cells has also been observed by o thers . 3 5 The combina­
tion of vessel wall components as depicted in the sche­
matic (Figure 1) can realistically lead to the initiation of 
neointimal formation which typifies vascular pathology 
in m a n and experimental animals. We have found that 
compounds such as TS, LDL, and Ang II are able, in 
cultured VSMC, of enhancing metabolic events nor­
mally associated with p ro l i f e ra t ion . 1 6 ' 2 0 ' 2 1 ' 2 8 ' 2 9 ' 3 6 TS 
alone was not mitogenic to VSMC, but, w h e n adminis­
tered in combination with EGF, its mitogenic potential 
was considerably enhanced . 8 ' 3 6 Al though there is no evi­
dence as yet to suggest the presence of EGF (or its close 
analogue T G F a ) in the normal vessel wall, recent data 
has shown that laminin, which is certainly present, pos­
sesses EGF-like sequences within its s t ructure . 3 7 It is 
conceivable that during the course of normal matrix 
turnover "EGF-like" molecules may arise and that these 
in combination with TS could behave as a strong mito­
genic mixture. Additionally, the stimulation of TGF^ ex­
pression by cultured smooth muscle cells in response to 
Ang II exposure 3 3 may account for the influence of the 
vasoactive peptide on matrix synthesis, since TGF^ has 
been shown to not only modulate the growth of smooth 
muscle cells but also to enhance their synthesis of extra-
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FIGURE 5. Growth kinetics of VSMC from SHR and WKY in 
presence and absence of Ang II. Cells were plated into 12-well 
multiwell plates (1.25 X 105 cells/well) in normal medium con­
taining 10% whole blood serum. After 18 h medium was replaced 
with 1% PDS medium (see Methods) and some wells were further 
supplemented with Ang II (5X108 mol/L) on a daily basis. Me­
dium (1% PDS) was changed every 48 h and cell numbers deter­
mined as described previously.18 Experiments (n = 3) were per­
formed on cells from (A) SHR and (B) WKY and the data represent 
the means ± SD. Statistical significance was analyzed using Stu­
dent's t test for unpaired data and the levels of significance are 
indicated on the figure as *, Ρ < .01; **, Ρ < .001. 
cellular matrix macromolecules . 3 8 In conclusion, it 
would appear that we no longer have to invoke damage 
to the endothel ium as the stimulus for the changes that 
lead to neointimal formation since many compounds 
such as Ang II, alone or in combination with normal 
constituents of the vessel wall, are potentially capable of 
pathogenic modulat ion of medial smooth muscle cells 
leading to progressive structural hypertrophy, as ob­
served in vascular tissue from hypertensive animals and 
man . 
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